Sjoerd Rodenhuis

Q: What Schools Are Affiliated With Sjoerd Rodenhuis

Sjoerd Rodenhuis is affiliated with the following schools: Leiden University, Aarhus University, University of Amsterdam, Delft University of Technology

Sjoerd Rodenhuis's AcademicInfluence.com Rankings

Sjoerd Rodenhuis

Medical

#3462

World Rank

#3931

Historical Rank

Oncology

#242

World Rank

#250

Historical Rank

medical Degrees

Sjoerd Rodenhuis

Philosophy

#9922

World Rank

#13552

Historical Rank

Logic

#6874

World Rank

#8431

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Sjoerd Rodenhuis's Degrees

Doctorate Medicine University of Amsterdam

Why Is Sjoerd Rodenhuis Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sjoerd Rodenhuis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
A gene-expression signature as a predictor of survival in breast cancer. (2002) (3325)
Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. (1998) (766)
Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. (1987) (547)
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. (1988) (494)
Clinical significance of ras oncogene activation in human lung cancer. (1992) (417)
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. (2005) (413)
Clinical Pharmacokinetics of Cyclophosphamide (1979) (373)
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome (2003) (302)
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). (2007) (277)
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer (2010) (265)
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. (2011) (264)
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. (2003) (261)
Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. (2002) (258)
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement (1998) (245)
ras and human tumors. (1992) (243)
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (2007) (240)
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. (1991) (236)
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of (2000) (226)
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom (2010) (194)
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. (1995) (191)
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers (2013) (190)
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. (2005) (189)
Malignant effusions contain lysophosphatidic acid (LPA)-like activity. (1998) (188)
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients (2010) (182)
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. (1994) (181)
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response (2009) (175)
K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung (1993) (153)
Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. (1995) (145)
The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy (2010) (139)
In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. (2001) (129)
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide (2008) (125)
The ras oncogenes in human lung cancer. (1990) (123)
18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques (2011) (121)
High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. (1990) (107)
Detection of circulating breast tumor cells by differential expression of marker genes. (2002) (106)
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver (1991) (105)
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. (2005) (103)
Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. (2008) (100)
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients (2003) (100)
Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation (2005) (100)
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. (2011) (99)
Overexpression of the p53 Tumor Suppressor Gene Product in Primary Lung Adenocarcinomas Is Associated with Cigarette Smoking (1993) (98)
Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. (1996) (96)
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy (2012) (96)
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. (1997) (95)
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy (2014) (93)
An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. (2009) (90)
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer (2012) (90)
Patient motivation and informed consent in a phase I study of an anticancer agent. (1984) (89)
Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. (1990) (88)
Comparative analysis of p53 gene mutations and protein accumulation in human non‐small‐cell lung cancer (1995) (87)
K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. (1993) (85)
Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high‐dose chemotherapy (2005) (82)
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response (2013) (81)
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. (2013) (80)
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. (2011) (80)
Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia. (1985) (80)
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. (1993) (78)
Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics (2012) (77)
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. (1997) (77)
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness (2011) (76)
Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. (1994) (75)
High-dose chemotherapy regimens for solid tumors. (1995) (75)
Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. (1986) (72)
The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. (1998) (71)
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. (2006) (71)
Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence–based amplification for the detection of circulating breast cancer cells (1999) (70)
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion (2000) (69)
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. (1995) (68)
Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy (2006) (68)
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (1999) (66)
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy (2006) (66)
A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. (1999) (64)
Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody (2005) (64)
Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy (2012) (62)
Management of intermediate‐prognosis germ‐cell cancer: Results of a phase I/II study of Taxol‐BEP (1999) (62)
Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism (2005) (61)
Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy (2013) (60)
Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. (2009) (59)
Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response (2015) (58)
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. (2002) (58)
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. (2002) (58)
Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. (2004) (55)
Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods (2000) (55)
The ras gene family in human non-small-cell lung cancer. (1992) (54)
N‐ and KRAS mutations in primary testicular germ cell tumors: Incidence and possible biological implications (1995) (54)
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? (2009) (53)
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin (2008) (52)
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer (2012) (52)
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. (1991) (51)
Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function (2006) (51)
Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens (2000) (50)
Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer. (1989) (49)
Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement (2004) (49)
A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. (2010) (47)
The clinical pharmacology of alkylating agents in high-dose chemotherapy. (2000) (47)
Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). (2007) (46)
Resistance to cisplatin and analogues: mechanisms and potential clinical implications. (1988) (46)
Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla (2013) (45)
Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. (1996) (45)
A Rapid and Simple Procedure for the Routine Detection of ras Point Mutations in Formalin‐Fixed, Paraffin‐Embedded Tissues (1992) (45)
Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy (2002) (44)
Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. (1992) (44)
High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. (1995) (44)
Combined use of 18F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy (2014) (43)
The molecular genetics of human lung cancer. (1989) (42)
Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin (2002) (42)
A Mechanism-Based Pharmacokinetic Model for the Cytochrome P450 Drug–Drug Interaction between Cyclophosphamide and ThioTEPA and the Autoinduction of Cyclophosphamide (2001) (42)
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. (1992) (41)
At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. (1999) (40)
Growth factors in human ovarian cancer. (1997) (39)
Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin (1995) (39)
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure (1996) (39)
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. (2009) (38)
Prognostic factors in NSCLC. Recent experiences. (1995) (38)
Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood (1986) (38)
The use of the Calvert formula to determine the optimal carboplatin dosage (2005) (37)
Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin (2005) (37)
Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer (2003) (35)
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. (2012) (33)
Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator. (1993) (32)
Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. (2007) (31)
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site (2020) (30)
Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin (2005) (28)
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF THE STABILIZED CYCLOPHOSPHAMIDE METABOLITE 4-HYDROXYCYCLOPHOSPHAMIDE IN PLASMA AND RED BLOOD CELLS (2000) (28)
Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography. (2000) (27)
Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. (1998) (27)
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients (2008) (26)
The status of high-dose chemotherapy in breast cancer. (2000) (26)
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (26)
Integrated Population Pharmacokinetic Model of Both Cyclophosphamide and Thiotepa Suggesting a Mutual Drug–Drug Interaction (2004) (26)
Resistance ot cisplatin and analogues: mechanisms and potential clinical implications (2004) (25)
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. (2001) (25)
A search for new metabolites of N,N',N''-triethylenethiophosphoramide. (1999) (25)
Absence of ras gene mutations in early gastric carcinomas. (1995) (24)
Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study (2004) (24)
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer (2013) (24)
Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. (1987) (23)
Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. (1986) (23)
Invasive pulmonary aspergillosis in a non-immunosuppressed patient: successful management with systemic amphotericin and flucytosine and inhaled amphotericin. (1984) (23)
Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience (2003) (22)
Breast cancer studies in the Netherlands (1996) (22)
Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. (2005) (21)
The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis. (1996) (21)
Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter. (1994) (21)
Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. (1999) (21)
Identifying subgroup markers in heterogeneous populations (2013) (20)
Serum beta2‐microglobulin: a real improvement in the management of multiple myeloma? (1985) (20)
Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. (2017) (19)
Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer. (2002) (19)
Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer (2016) (19)
Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II–III breast cancer patients treated with neoadjuvant chemotherapy (2013) (19)
Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes (2017) (18)
Monitoring Carboplatin Concentrations in Saliva: A Replacement for Plasma Ultrafiltrate Measurements? (1995) (18)
Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer. (1993) (18)
Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. (1995) (18)
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study. (1989) (17)
Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. (1991) (17)
Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. (1997) (17)
Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. (1997) (17)
Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. (1996) (16)
Sampling technique from central venous catheters proves critical for pharmacokinetic studies. (1999) (16)
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support (1995) (15)
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen (1999) (15)
Oncogenes and human lung cancer. (1989) (15)
Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer (2001) (15)
[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]. (2008) (14)
Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency (2008) (14)
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (14)
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma (2001) (13)
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute. (1992) (13)
Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes (2005) (13)
Paclitaxel, Carboplatin, and Trastuzumab in a Neo‐adjuvant Regimen for HER2‐positive Breast Cancer (2013) (13)
Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours. (1996) (13)
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. (1993) (13)
Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin (2001) (12)
Association of H‐ras mutations with adenocarcinomas of the parotid gland (1994) (12)
Inefficacy of Plasma Exchange in Cold Agglutinin Hemolytic Anemia — A Case Study (1985) (11)
Successful intraperitoneal suramin treatment of peritoneal mesothelioma. (1997) (11)
EAP in advanced gastric cancer. (1990) (11)
Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer. (1992) (11)
Carbamazepine induces bioactivation of cyclophosphamide and thiotepa (2009) (11)
Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells. (1987) (11)
A Method to Monitor mRNA Levels in Human Breast Tumor Cells Obtained by Fine‐needle Aspiration (1997) (11)
Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study. (1989) (11)
Allele‐specific detection of K‐ras oncogene expression in human non‐small‐cell lung carcinomas (2007) (10)
Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma. (2001) (10)
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study. (1999) (10)
Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination (2004) (10)
Invasive aspergillosis complicated by subclavian artery occlusion and costal osteomyelitis after autologous bone marrow transplantation. (1992) (9)
Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography. (1998) (9)
0073 The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer (2009) (9)
High-dose chemotherapy in breast cancer - interpretation of the randomized trials (2001) (9)
Validation of a Therapeutic Drug Monitoring Strategy for Thiotepa in a High-Dose Chemotherapy Regimen (2001) (9)
Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes (2014) (9)
Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization. (2009) (9)
Neutropenic enterocolitis in a patient with ovarian cancer after treatment with high-dose carboplatin and granulocyte macrophage-colony stimulating factor (GM-CSF). (1990) (9)
Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy (2000) (9)
Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients (2008) (8)
Sorption of Thiotepa to Polyurethane Catheter Causes Falsely Elevated Plasma Levels (2003) (8)
Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (PSCT) in Patients with Malignant Lymphomas and Solid Tumors (1993) (8)
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone (2004) (8)
A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive epithelial ovarian cancer (eoc) (2010) (8)
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. (2012) (7)
Is high-dose chemotherapy dead? (2005) (7)
Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel (2007) (7)
Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer (2017) (7)
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure (2015) (6)
Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer (2004) (6)
Sparse Sampling Design for Therapeutic Drug Monitoring of Sequentially Administered Cyclophosphamide, Thiotepa, and Carboplatin (CTC) (2005) (6)
Prediction of response to neoadjuvant chemotherapy in breast cancer. (2006) (6)
Effect of Cisplatin-Containing Chemotherapy on Lithium Serum Concentrations (1992) (6)
Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer. (1992) (6)
Early onset of oral aphthous ulcers with weekly docetaxel. (2005) (6)
Clinical pharmacokinetics of (NPAz2)2NSOAz: ‘SOAz’ (2004) (5)
High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer. (2000) (5)
Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions. (1996) (5)
Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies (2008) (5)
Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers. (1988) (4)
Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer : Update of the Dutch randomized (2005) (4)
Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy. (2003) (4)
Downstaging of an Advanced Gastrointestinal Stromal Tumor by Neoadjuvant Imatinib (2004) (4)
Pharmacokinetics of Cyclophosphamide and Thiotepa in a Conventional Fractionated High-Dose Regimen Compared With a Novel Simplified Unfractionated Regimen (2009) (4)
Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient? (2015) (4)
Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion (1996) (4)
Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: a dose-finding study. (1993) (4)
Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial (2005) (4)
PP-5-1 Preliminary analysis of a randomized phase II study of high-dose chemotherapy in high-risk breast cancer (1996) (3)
NEW DESIGNS AND STRUCTURE ACTIVITY RELATIONSHIPS IN ANTITUMORAL AZIRIDINYL CYCLOPHOSPHA(THIA)ZENES (1983) (3)
Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology. (2009) (3)
940 Phase I and pharmacokinetic study of topotecan (T) in combination with oral etoposide (E) (1995) (3)
Tauromustine (TCNU) combined with 5-fluorouracil and leucovorin in the treatment of advanced colon cancer. (1993) (3)
Phase i clinical trial of (NPAz2)2NSOAz: ‘SOAz’ (2004) (3)
Phase I evaluation of SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6, 2,4,6,3 lambda 5, 5 lambda 5 thiatriaza-diphosphorine-1-oxide) in a weekly schedule. (1984) (3)
Oral Bioavailability of Low Dose (20mg) ‘Home-Made’ Etoposide Capsules (1996) (3)
Reconstitution of interleukin-2 (1990) (3)
0074 Early prognosis prediction: MammaPrint on core-needle biopsies (2009) (2)
Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer. (2004) (2)
Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness, and as such treatment response. (2011) (2)
PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease. (2017) (2)
[Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. (2006) (2)
A randomized single-institution study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin (CTC) in apical node-positive breast cancer (1997) (2)
Genomic patterns resembling BRCA-mutated breast cancers and benefit of intensified carboplatin-based chemotherapy in HER2-negative breast cancer. (2011) (2)
P3-14-17: Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant Regimen for HER2−Positive Breast Cancer: The TRAIN Study. (2011) (2)
Determination of the antitumor agent SOAz (1,3,3,5,5 Pentakis(Aciridino)-1λ6,2,4,6,3λ5,5λ5 Thia-Triazadiphosphorine-1-Oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in man (2004) (2)
The Diagnosis of Tumors. (1946) (2)
7 Relevance of Breast Cancer Subtypes in Response Monitoring with 18F-FDG PET/CT During Neoadjuvant Chemotherapy (2012) (2)
Interpretation of contrast enhanced MRI for early prediction of breast-cancer response to neoadjuvant chemotherapy: Initial results (2008) (2)
Clinical pharmacokinetics of (NPAz 2 ) 2 NSOAz: SOAz (1983) (2)
12 Multiple courses of high-dose alkylating therapy with autologous stem cell support (1995) (1)
Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle (2017) (1)
Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer (2005) (1)
Dose-intensive chemotherapy for locally advanced breast cancer (1999) (1)
High-dose chemotherapy in breast cancer. The Dutch trial (2001) (1)
Third-party payers and breast cancer study. (1998) (1)
Comprehensive characterization of matched pre-treatment biopsies and residual disease of chemotherapy treated breast cancer (2016) (1)
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxatrone (Short communication) (1992) (1)
High-dose chemotherapy in solid tumors (1999) (1)
An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy. (2013) (1)
First experiences with the use of imatinib in gastrointestinal stromal tumours (2006) (1)
High-dose chemotherapy for breast cancer - To the editor (1997) (1)
[High-dose chemotherapy with stem cell support for solid tumors in adults]. (1999) (1)
New treatment opportunities in non-small cell lung cancer (1993) (1)
Gunstig effect van uit het bloed geïsoleerde hematopoëtische stamcellen op het hematologisch herstel na hooggedoseerde chemotherapie (1993) (1)
Homologous recombination defects in sporadic breast cancers (2008) (1)
High-Dose Chemotherapy for Breast Cancer (1997) (1)
[Recurrent upper respiratory tract infections during and after rituximab therapy]. (2015) (1)
High-dose chemotherapy for breast cancer - Reply (2003) (1)
Joint Accreditation Committee of the International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation accreditation for autologous hematopoietic stem cell transplantation in non-leukemic malignancies: burden or benefit? (2016) (1)
The pharmacokinetics of reduced folates after intraperltoneal and intravenous administration of racemic [6S,R]-folinic acid (2004) (1)
258 Evaluation of radioactive seed versus radio guided localization in breast conserving surgery after primary systemic therapy (2010) (1)
Abstract P4-02-01: 18F-FDG PET/CT for the assessment of locoregional lymph node involvement and radiotherapy indication in stage II-III breast cancer treated with neoadjuvant chemotherapy (2012) (1)
A High-Dose Carboplatin-Based Salvage Strategy for Relapsing or Refractory Germ Cell Cancer (1994) (1)
ras oncogene activation and the expression of ras-related genes in human lung cancer (1993) (1)
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients. (1997) (1)
Clinical relevance of the use of FDG PET/CT in locally advanced breast cancer. (2012) (1)
Abstract PD07-07: Indicators of Homologous Recombination Deficiency in Breast Cancer and Association with Response to Neoadjuvant Chemotherapy (2010) (1)
High-dose chemotherapy and stem-cell support in breast cancer (multiple letters) [1] (1998) (0)
Randomized studies of high dose chemotherapy in high-risk breast cancer in The Netherlands (1999) (0)
970O CARBOPLATIN PLUS PACLITAXEL VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN AS FIRST- LINE TREATMENT FOR PATIENTS WITH OVARIAN CANCER: THE MITO-2 (MULTICENTRE ITALIAN TRIALS IN OVARIAN CANCER) RANDOMIZED PHASE III TRIAL (2010) (0)
Detection of homologous recombination defects in biopsies of sporadic breast cancers (2008) (0)
Abstract 1192: Triple negative breast cancer: BRCAness and concordance of clinical features and treatment response with BRCA1 mutation carriers. (2013) (0)
The role of high-dose chemotherapy in breast cancer (2006) (0)
Risk factors for early recurrences after conventional- or high-dose adjuvant chemotherapy in breast cancer patients with extensive lymph node involvement (2004) (0)
Cognitive functions after chemotherapy (2004) (0)
Fulvestrant in heavily pre-treated breast cancer patients-Single institution experience. (2006) (0)
139. Relevance of breast cancer subtypes in response monitoring with 18F-FDG PET/CT during neoadjuvant chemotherapy (2012) (0)
155. Locoregional lymph node involvement on 18F-FDG PET/CT and estimation of risk for locoregional recurrence in stage II–III breast cancer patients (2012) (0)
Abstracts of papers Pharmaceutical and biomedical analysis meeting (2005) (0)
Chemotherapie mammacarcinoom (2003) (0)
Prospective analysis of mRNA expression signatures as predictive tests in primary breast cancer (2007) (0)
GYNECOLOGIC ONCOLOGY ISSUES IN THE 8TH IGCS MEETING OF BUENOS AIRES (2000) (0)
Reviewers of the Journal of Chemotherapy (2010) (0)
Preventie en therapie van tumoren (2002) (0)
Erratum: Predicting early failure in node-positive breast cancer (Clinical Cancer Research (July 1)) (2004) (0)
Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response (2015) (0)
High-dose chemotherapy in breast cancer: Dutch randomized studies (2001) (0)
[A look over the horizon of cancer treatment. The internist]. (1989) (0)
High-dose chemotherapy and stem-cell support in breast cancer (1998) (0)
PP65. Economic evaluation of high dose chemotherapy for breast cancer patients (1997) (0)
Abstract P3-06-21: Next generation sequencing to find predictors for chemotherapy response in triple negative breast cancer (2015) (0)
High-dose chemotherapy and stem-cell support in breast cancer. Authors' reply (1998) (0)
Genotyping as tool for dose individualisation in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin (2005) (0)
[Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy]. (1993) (0)
Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site (2023) (0)
Abstract 4820: A clinical test for BRCAness: Using array comparative genomic hybridization to predict benefit of high-dose, platinum-containing chemotherapy in ER-low/HER2-negative breast cancer patients (2010) (0)
OC-0130 18F-FDG PET/CT FOR THE ASSESSMENT OF LOCOREGIONAL LYMPH NODE INVOLVEMENT IN STAGE II AND III BREAST CANCER (2012) (0)
Invasive pulmonary aspergillosis inanon-immunosuppressed patient: successful managementwithsystemic amphotericin andflucytosine andinhaled amphotericin (1984) (0)
Abstract PD1-07: Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer (2017) (0)
Abstract 3134: Neoadjuvant chemotherapy in ER+HER2- breast cancer: Response prediction based on immunohistochemical and molecular characteristics (2011) (0)
REVIEW OF CARBOPLATIN-BASED HIGH-DOSE CHEMOTHERAPY COMBINATIONS IN THE AUTOTRANSPLANT SETTING (1996) (0)
Managing patients at home during the aplastic phase of high dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT) (1999) (0)
High-dose chemotherapy in breast cancer : In favor! (2000) (0)
1st National Congress of the Hellenic Society of Digestive Surgery (2004) (0)
Detection of minimal disease in breast cancer (2005) (0)
Individualized chemotherapy doses with granulocyte colony stimulating factor support have survival and toxicity benefits over marrow supported high dose chemotherapy (2001) (0)
HIGH-DOSE CHEMOTHERAPY FOR BREAST CANCER. AUTHOR'S REPLY (1997) (0)
PD03-08: BRCA1-Like Triple Negative Tumors: Clinicopathological Variables and Chemosensitivity to Alkylating Agents. (2011) (0)
Benefit of the 70-gene profile for widely used guidelines: an answer to increased selection for adjuvant chemotherapy in breast cancer. (2009) (0)
Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer (2016) (0)
Prevention and therapy of tumors (2002) (0)
Early Clinical Studies of (NPAz2)2NSOAz (1983) (0)
Next-generation sequencing to find predictors for chemotherapy response in triple-negative breast cancer (TNBC). (2013) (0)
Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy. (2012) (0)
Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer (2005) (0)
Abstract 22: Identifying chemotherapy resistance genes using outlier detection (2011) (0)
Abstract PD06-06: Novel Surgical Technique To Assess the Response of Metastatic Axillary Lymph Nodes to Neoadjuvant Chemotherapy in Breast Cancer Patients (2010) (0)
Determination of the antitumor agent SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6,2,4,6,3 lambda 5, 5 lambda 5 thia-triazadiphosphorine-1-oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in man. (1983) (0)
Abstract OT1-1-01: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - The TRAIN-2 study (2013) (0)
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy (2014) (0)
[Centralising cancer treatment: a good idea]. (2011) (0)
High dose chemotherapy in breast cancer reviewed (1995) (0)
EZH2 is overexpressed in breast tumors with a BRCA1-like DNA copy number profile (2015) (0)
Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study (2016) (0)
P72. Prediction of response to preoperative chemotherapy in locally advanced breast cancer (2006) (0)
P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial. (2011) (0)
Drug resistance. (1989) (0)
High-dose chemotherapy in breast cancer—a critical review (2006) (0)
Early Clinical Studies of (NPAz2)2NSOAz: 'SOAz' (1983) (0)
Abstract 1751: Systematic bias in genomic breast cancer classification due to selecting cases with high tumor percentage and good RNA quality (2017) (0)
10 Homologous recombination deficiency in breast cancer and association with response to neo-adjuvant chemotherapy (2010) (0)
Chapterr 4. Phasee II study of a multi-course high-dose chemotherapy regimen incorporatingg cyclophosphamide, thiotepa, and carboplatin in stagee IV breast cancer (2007) (0)
Abstract PD01-04: Histological Features of ER-Low, HER2-Negative Breast Cancer Predict Response to High Dose, Platinum-Based Chemotherapy (2010) (0)
Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04) (2017) (0)
Impact of polymorphisms in the CYP2B6 gene on the pharmacokinetics of cyclophosphamide and thiotepa. (2006) (0)
Relevance of histological and molecular subtypes in the outcome of primary systemic therapy for operable breast cancer (2008) (0)
A phase Istudy ofprolonged continuous infusion oflowdoserecombinant interleukin-2 inmelanoma andrenal cellcancer.PartI:clinical aspects (1992) (0)
Diagnose van tumoren (2002) (0)
Dutch studies of high-dose chemotherapy with hematopoietic progenitor cell support in high-risk breast cancer (1998) (0)
Adjuvant therapy for breast cancer (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sjoerd Rodenhuis?

Sjoerd Rodenhuis is affiliated with the following schools:

Sjoerd Rodenhuis's Academic­Influence.com Rankings

Sjoerd Rodenhuis's Degrees

Why Is Sjoerd Rodenhuis Influential?

Sjoerd Rodenhuis's Published Works

Published Works

What Schools Are Affiliated With Sjoerd Rodenhuis?

Sjoerd Rodenhuis's AcademicInfluence.com Rankings